Early access to experimental AML drug ABBV-787 now available for some patients
NCT ID NCT06439966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia (AML) who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by regulators.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.